On the afternoon of May 8, 2026, a delegation led by Mao Lili, Chairman of Bioland Laboratory and Jian Shi Ke Chuang, together with experts from Guangzhou National Laboratory and the Stomatological Hospital of Guangzhou Medical University, visited Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd. for site inspection and discussions. The two sides held in-depth talks on key topics including the construction of core technology platforms for cell and gene therapy, clinical research and translational application of emerging biomedical technologies, translation of scientific research outcomes, and hospital-enterprise collaborative innovation.

The visiting delegation included Mao Lili, Assistant to the Director of Bioland Laboratory, Executive Dean of the Whampoa Academy, and Chairman of Jian Shi Ke Chuang; Liu Huisheng, Researcher at Guangzhou National Laboratory and Chief Scientist of the Cell Technology Platform; Zhang Wei, Researcher at Guangzhou National Laboratory and Chief Scientist of the Imaging Technology Platform; Sun Jiaqi and Yin Jiaxiang, Associate Researchers at Guangzhou National Laboratory; Liang Yefei, CGT Marketing Specialist at Bioland Laboratory; Professor Zhang Qingshan, Party Secretary, Professor, Chief Physician, and Doctoral Supervisor at the Stomatological Hospital of Guangzhou Medical University; Li Xingyang, Supervisor of the Medical Affairs Department; and Huang Zhiqing, Postdoctoral Fellow. Representing Shenzhen Cell Valley were Shi Yuanyuan, Chairman and General Manager; Wang Jianxun, Chief Scientist; Xiang Hua, Deputy General Manager; Zhao Lijun, Head of R&D; and Sun Rui, Head of Marketing.

The delegation first toured the Cell Valley's smart exhibition hall and administrative areas on the 13th floor, followed by a site visit to the production workshop and R&D laboratory on the 12th floor, where they gained detailed insight into the company's capabilities in CRO/CDMO services for cell and gene therapy, clinical-grade cell manufacturing, industrial-scale production of viral vectors, exosome technology platforms, quality management systems, and clinical research services for emerging biomedical technologies.

During the symposium, Shenzhen Cell Valley presented its platform-based capabilities across key segments of the cell and gene therapy industrial chain, with a focus on its technical accumulation in retroviral vectors, lentiviral vectors, AAV, engineered eVLP pseudoviral vectors, immune cell therapy, stem cells, and exosomes, as well as its one-stop service system for clinical research and translational application of emerging biomedical technologies for hospitals. The company noted that with the implementation of the Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies, the cell and gene therapy industry is entering a new phase of standardization, platform-based development, and clinical-value orientation, and that synergy among high-level research platforms, clinical hospitals, and industrial platforms will become a key pathway for moving original research outcomes toward clinical application.

Experts from Bioland Laboratory and Guangzhou National Laboratory engaged in in-depth exchanges with the Shenzhen Cell Valley team on areas including cell technology platforms, imaging technology platforms, frontier technology validation, preclinical uation, and result translation mechanisms. Both sides agreed that the translational application of cell and gene therapy technologies requires not only original scientific breakthroughs but also mature and stable support systems for process development, GMP-grade manufacturing, quality control, clinical research design, and compliant translation. Future collaboration could be further strengthened in areas such as cell therapy, gene delivery, exosomes, regenerative medicine, imaging uation, and clinical research technology services.

Experts from the Stomatological Hospital of Guangzhou Medical University, drawing on clinical needs in stomatology, discussed the application prospects of cell therapy, engineered exosomes, and tissue repair and regenerative medicine technologies in oral and maxillofacial reconstruction, periodontal tissue regeneration, and oral cancer treatment. Both sides recognized that stomatology presents clear clinical scenarios and translational needs, with strong potential for integration with cell and gene technologies, regenerative medicine, and novel delivery systems. Future cooperation could explore models such as clinical research project design, standardized management of samples and data, and hospital-enterprise joint translation.

This exchange laid a solid foundation for further cooperation between the Cell Valley Group and Bioland Laboratory, Guangzhou National Laboratory, and the Stomatological Hospital of Guangzhou Medical University. Cell Valley will continue to leverage its advantages as a one-stop service platform for cell and gene therapy and a clinical translation platform for emerging biomedical technologies, actively connecting high-level research institutions, clinical hospitals, and industrial resources in the Guangdong-Hong Kong-Macao Greater Bay Area, promoting efficient alignment of original technologies, clinical needs, and industrial capabilities, and contributing to the high-quality development of China's cell and gene therapy industry.